VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Scholar Rock Holding Executive Compensation (FY25)

SRRK · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
David Hallal
Latest say-on-pay support
=
June 4, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Scholar Rock Holding brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 5, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Scholar Rock Holding brief$500Get the executive brief
Velarion Intel, one year, every company
183 figures on this page: 180 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive of record: Jay Backstrom → David Hallal
Say-on-pay support: 96.3% → 61.7% (34.6 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Scholar Rock Holding's chief executive and what were they paid?
David Hallal was paid $33,300,927 in total compensation as Chief Executive Officer and Chairman for fiscal 2025.
What was Scholar Rock Holding's say-on-pay result?
Shareholders supported the say-on-pay proposal with 61.7% of votes cast for or against in favor at the meeting held June 4, 2026 for fiscal 2025.
Which companies are in Scholar Rock Holding's peer group?
The disclosed peer group names Agios Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc. and Avidity Biosciences, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jay Backstrom
President, and Chief Executive Officer
◇——◇◇—◇◇
Edward Myles
Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jay Backstrom
President, and Chief Executive Officer
◇—◇◇◇—◇◇
Tracey Sacco
Chief Commercial Officer
◇◇—◇◇—◇— not reconciled
Edward Myles
Chief Operating Officer and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jay Backstrom
President, and Chief Executive Officer
◇—◇◇◇—◇◇
Jing Marantz
Chief Medical Officer
◇—◇◇◇—◇◇
Mo Qatanani
Chief Scientific Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
David Hallal
Chief Executive Officer and Chairman
◇◇◇◇◇—◇◇
Jay Backstrom
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇——◇◇
Akshay Vaishnaw
President of R&D
◇◇◇◇◇—◇◇
R. Keith Woods
Chief Operating Officer
◇—◇◇◇—◇◇
Vikas Sinha
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Akshay VaishnawOption——————◇
Akshay VaishnawPRSU——————◇
David HallalPRSU——————◇
David HallalOption——————◇
Jay BackstromOption——————◇
Jay BackstromPRSU——————◇
R. Keith WoodsOption——————◇
R. Keith WoodsPRSU——————◇
Vikas SinhaPRSU——————◇
Vikas SinhaOption——————◇
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
David HallalPSU◇◇——
Option◇—◇5/2/2035
Option◇—◇5/2/2035
RSU◇◇——
Vikas SinhaPSU◇◇——
Option◇—◇5/2/2035
Option◇—◇5/2/2035
RSU◇◇——
Akshay VaishnawPSU◇◇——
Option◇—◇5/2/2035
Option◇—◇5/2/2035
RSU◇◇——
R. Keith WoodsOption◇—◇05/02/2035
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Akshay Vaishnaw
President of R&D · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
David Hallal
Chief Executive Officer and Chairman · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
R. Keith Woods
Chief Operating Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Vikas Sinha
Chief Financial Officer · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey S. Flier, M.D
◇◇◇———◇
Joshua Reed
◇◇◇———◇
Katie Peng
◇◇◇———◇
Kristina Burow
◇◇◇———◇
Michael Gilman, Ph.D
◇◇◇———◇
Srinivas Akkaraju, M.D., Ph.D
◇◇◇———◇
Richard Brudnick
◇◇◇———◇
Jay Backstrom, M.D., M.P.H, Akshay Vaishnaw, M.D., Ph.D and David Hallal served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agios Pharmaceuticals, Inc. AGIO
  • Apellis Pharmaceuticals, Inc. APLS
  • Arcus Biosciences, Inc. RCUS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Avidity Biosciences, Inc. RNAM
  • Axsome Therapeutics, Inc. AXSM
  • Biohaven Ltd. BHVN
  • Blueprint Medicines Corporation BPMC
  • BridgeBio Pharma, Inc. BBIO
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Day One Biopharmaceuticals, Inc. DAWN
  • Denali Therapeutics Inc. DNLI
  • Dyne Therapeutics, Inc. DYN
  • Madrigal Pharmaceuticals, Inc. MDGL
  • PTC Therapeutics, Inc. PTCT
  • Rhythm Pharmaceuticals, Inc. RYTM
  • Rocket Pharmaceuticals, Inc. RCKT
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX
  • Ultragenyx Pharmaceutical Inc. RARE
  • Viridian Therapeutics, Inc. VRDN

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 4, 2026=◇◇◇
2024May 22, 2025=◇◇◇
2023June 27, 2024=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- David Hallal (Chief Executive Officer and Chairman), FY2025 total compensation $33,300,927 (base salary $637,500) [exec_comp, SEC accession 0001104659-26-046917, filed 2026-04-22]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Scholar Rock Holding files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Scholar Rock Holding disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Scholar Rock Holding sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Say-on-pay responsiveness
Scholar Rock Holding recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysis
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Scholar Rock Holding's disclosed peer group is defensible, who names Scholar Rock Holding back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
183 figures on this page: 180 cited to the filing that reported them, 3 calculated from figures it prints.
180 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001104659-26-070636
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-046917
    DIRECTOR COMPENSATION · Summary Compensation Table · Summary Compensation Table for Fiscal 2025
  3. 0001558370-25-010400
    EX-10.25 · EX-10.26 · EX-10.27 · EX-10.28
  4. 0001558370-25-008134
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001104659-25-033970
  6. 0001558370-24-009582
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-24-053978
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Scholar Rock Holding executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/SRRK (accessed 2026).
Short form: data: Velarion

The Scholar Rock Holding brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Scholar Rock Holding and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Scholar Rock Holding discloses

The companies named in SRRK's own disclosed peer group.

Agios Pharmaceuticals, Inc.Apellis Pharmaceuticals, Inc.Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Avidity Biosciences, Inc.Axsome Therapeutics, Inc.Biohaven Ltd.Blueprint Medicines CorporationBridgeBio Pharma, Inc.Crinetics Pharmaceuticals, Inc.Day One Biopharmaceuticals, Inc.Denali Therapeutics Inc.Dyne Therapeutics, Inc.Madrigal Pharmaceuticals, Inc.PTC Therapeutics, Inc.Rhythm Pharmaceuticals, Inc.Rocket Pharmaceuticals, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.Viridian Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy